Centogene
Chris Eberlein has a diverse work experience spanning various roles and industries.
From 2021 to present, Chris has been working at CENTOGENE, initially holding the position of Head of Product & Method Development and currently serving as the Director of Product & Method Development.
Prior to joining CENTOGENE, Chris worked as a Postdoctoral Researcher at the University of Strasbourg from March 2019 to December 2020.
Before that, they pursued their PHD at Université Laval, where they worked as a PHD Student from September 2014 to December 2018.
Additionally, Chris gained valuable sales and teaching experience during their studies through a side job at Insider Traveller GmbH. Chris served as a Salesman and Kajaking guide, where they sold outdoor equipment and taught kayaking, climbing, and nature-related activities to school classes from 2007 to 2012.
Chris Eberlein holds a Bachelor's degree in Evolutionary Biology from Ruhr University Bochum, which they completed in 2010. In 2009, they participated in an Erasmus exchange semester at the University of Bergen (UiB), focusing on Bioinformatics and Marine Ecology. In 2010, they conducted an external Bachelor's thesis at the Alfred-Wegener Institude for Polar and Marine Research. Chris then pursued a Master's degree in Ecology and Evolutionary Biology at Ruhr University Bochum from 2010 to 2012. Chris continued their graduate studies at the University of Helsinki from 2012 to 2014, specializing in the field of Ecology and Evolutionary Biology. Finally, Chris received their Doctor of Philosophy (PhD) in Genome Sciences/Genomics from Université Laval, which they completed in 2018.
Centogene
2 followers
Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450, 000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients' blood samples. In addition, it is active in the research and development products for human genetics. The Company operates in Germany and the United States.